One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...

and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

While palmoplantar psoriasis can be harder to manage than psoriasis of the body, the options for palmoplantar psoriasis treatment are more or less ... quality of life compared to moderate-to-severe ...